Orally for long-term treatment of pathologic hypersecretory conditions, including Zollinger-Ellison syndrome. Discontinue IV therapy as soon as patient is able to initiate or resume oral therapy with the drug. IV for up to 7–10 days in the treatment of GERD in patients with a history of erosive esophagitis. Orally to maintain healing and decrease recurrence of erosive esophagitis. Orally for short-term treatment of erosive esophagitis in patients with GERD. Uses for Pantoprazole Gastroesophageal Reflux (GERD) IntroductionĪcid- or proton-pump inhibitor gastric antisecretory agent. For additional information, see the ASHP website. The drug is included in a standard concentration list which may apply to an IV or oral compounded liquid formulation. A standardized concentration for this drug has been established through Standardize 4 Safety (S4S), a national patient safety initiative to reduce medication errors, especially during transitions of care.
0 kommentar(er)
